FHIR IG analytics| Package | hl7.fhir.us.mcode.r4 |
| Resource Type | MedicationAdministration |
| Id | MedicationAdministration-cancer-related-medication-admin-doxorubicin-jenny-m.json |
| FHIR Version | R4 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: MedicationAdministration cancer-related-medication-admin-doxorubicin-jenny-m
Normalization Basis Extension: Body weight characteristic (observable entity)
status: Completed
category: Outpatient
medication: 10 ML doxorubicin hydrochloride 2 MG/ML Injection
subject: Jenny M Female, DoB: 1965-01-01 ( Medical Record Number: MRN1234 (use: usual, ))
effective: 2018-04-22
| Actor |
| Practitioner Nancy Nurse |
reasonReference: Condition Primary malignant neoplasm of female left breast (disorder)
note: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2018-04-22)
| Route | Dose |
| Intravenous route (qualifier value) | 105.96 mg (Details: UCUM codemg = 'mg') |
{
"resourceType": "MedicationAdministration",
"id": "cancer-related-medication-admin-doxorubicin-jenny-m",
"meta": {
"profile": [
"http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
]
},
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-normalization-basis",
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "363804004",
"display": "Body weight characteristic (observable entity)"
}
]
}
}
],
"status": "completed",
"category": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/medicationrequest-category",
"code": "outpatient"
}
]
},
"medicationCodeableConcept": {
"coding": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"code": "1790099",
"display": "10 ML doxorubicin hydrochloride 2 MG/ML Injection"
}
]
},
"subject": {
"reference": "Patient/cancer-patient-jenny-m"
},
"effectiveDateTime": "2018-04-22",
"performer": [
{
"actor": {
"reference": "Practitioner/us-core-practitioner-nancy-oncology-nurse"
}
}
],
"reasonReference": [
{
"reference": "Condition/primary-cancer-condition-jenny-m"
}
],
"request": {
"reference": "MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m"
},
"note": [
{
"authorReference": {
"reference": "Practitioner/us-core-practitioner-nancy-oncology-nurse"
},
"time": "2018-04-22",
"text": "doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."
}
],
"dosage": {
"route": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "47625008",
"display": "Intravenous route (qualifier value)"
}
]
},
"dose": {
"value": 105.96,
"unit": "mg",
"system": "http://unitsofmeasure.org",
"code": "mg"
}
}
}